摘要
Objective To investigate the effects of recombinant human endostatin,that is,endostar combined with gemcitabine on the mouse model of human pancreatic cancer.Methods We use the cell line PANC-1 and the severe combined immune deficient mice to set up the mouse model of human pancreatic cancer,then devide them into three groups,treat them with gemcitabine, gemcitabine combined with endostar,and 0.9% saline water respectively.We observe the change of the tumor volumn,use ELISA method to detect the serum VEGF level,stain the micro vessel in the tumor tissue with immunohistochemistry method,and compare the data among the different groups respectively.Results On the twenty-eighth day,the tumor volume of the control group,the monotherapy group and the combination group,averaged 1 700 mm3,19.2 mm3,10.4 mm3,serum VEGF level 88.6 L,35.5,26.3 pg/mL and MVD 43.9,30.3,19.2 respectively,which had significant difference.Conclusion Endostar can strengthen the lethal effect of gemcitabine on the mouse model of human pancreatic cancer.
Objective To investigate the effects of recombinant human endostatin, that is, endostar combined with gemcitabine on the mouse model of human pancreatic cancer. Methods We use the cell line PANC-1 and the severe combined immune deficient mice to set up the mouse model of human pancreatic cancer, then devide them into three groups, treat them with gemcitabine, gemcitabine combined with endostar, and 0.9 % saline water respectively. We observe the change of the tumor volumn, use ELISA method to detect the serum VEGF level, stain the micro vessel in the tumor tissue with immunohistochemistry method, and compare the data among the different groups respectively. Results On the twenty-eighth day, the tumor volume of the control group, the monotherapy group and the combination group, averaged 1 700 mm^3, 19. 2 mm^3, 10.4 mm^3, serum VEGF level 88.6 L, 35.5, 26.3 pg/mL and MVD 43.9, 30.3, 19. 2 respectively, which had significant difference. Conclusion Endostar can strengthen the lethal effect of gemcitabine on the mouse model of human pancreatic cancer.
出处
《实用临床医药杂志》
CAS
2007年第2期19-23,共5页
Journal of Clinical Medicine in Practice
基金
江苏省卫生厅科研指导性课题(Z200504)
